Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Up 826.1% in February

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 1,226,671 shares, an increase of 826.1% from the January 29th total of 132,462 shares. Based on an average daily volume of 6,360,187 shares, the days-to-cover ratio is presently 0.2 days. Approximately 19.6% of the shares of the stock are short sold. Approximately 19.6% of the shares of the stock are short sold. Based on an average daily volume of 6,360,187 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On Biorestorative Therapies

Several large investors have recently made changes to their positions in the company. DRW Securities LLC acquired a new stake in Biorestorative Therapies in the fourth quarter worth about $55,000. Citadel Advisors LLC bought a new stake in shares of Biorestorative Therapies during the third quarter worth approximately $152,000. Finally, Virtu Financial LLC raised its stake in shares of Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after buying an additional 12,319 shares during the last quarter. Institutional investors and hedge funds own 69.38% of the company’s stock.

Biorestorative Therapies Trading Down 16.5%

Shares of Biorestorative Therapies stock traded down $0.04 during midday trading on Wednesday, reaching $0.23. The company had a trading volume of 14,230,726 shares, compared to its average volume of 8,840,344. The stock has a fifty day simple moving average of $0.96 and a 200 day simple moving average of $1.27. Biorestorative Therapies has a 1-year low of $0.19 and a 1-year high of $2.28. The company has a market capitalization of $2.04 million, a price-to-earnings ratio of -0.15 and a beta of 0.39.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.